What does this research mean for the field?

In Chinese patients with non-small cell lung cancer, EGFR mutations are predominantly classical-like, and the presence of compound or co-occurring EGFR mutations significantly reduces the clinical efficacy of tyrosine kinase inhibitors. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To examine the distribution of structurally classified EGFR mutations and determine the sensitivity of compound and co-occurring EGFR mutations to tyrosine kinase inhibitors (TKIs) in Chinese patients with non-small cell lung cancer.

September 8, 2026BMC CancerOpen Access

Structural classification of EGFR mutations and its association with TKI efficacy against compound and co-mutations in a Chinese NSCLC cohort: a single-center retrospective analysis

View Full Paper

Ask AI

Bookmark

To examine the distribution of structurally classified EGFR mutations and determine the sensitivity of compound and co-occurring EGFR mutations to tyrosine kinase inhibitors (TKIs) in Chinese patients with non-small cell lung cancer.
Retrospective single-center study analyzing tumor samples from 452 patients with non-small cell lung cancer using next-generation sequencing across multiple oncogenic driver genes.
Categorized EGFR mutations into four structural subgroups (classical-like, T790M-like, Ex20ins-L, and PACC) and evaluated TKI sensitivity in 28 patients with compound EGFR mutations and 39 patients with EGFR co-mutations alongside clinicopathological associations.
Genomic alterations were detected in 81.64% of patients, with EGFR being the most frequent (53%), followed by KRAS (13%) and ALK (11%).
Among EGFR-mutant cases, 80.33% were classical-like (50% L858R, 46.88% exon 19 deletions), 6.69% T790M-like, 4.60% PACC, and 3.35% Ex20ins-L.
Patients with compound EGFR mutations experienced significantly worse clinical response to first-line TKIs compared to those with single classical mutations (P = 0.022), and co-mutations similarly reduced TKI sensitivity (P = 0.045).

Authors

RLRui Liu XXXiaofang Xie DYDan Yu

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective study uncovers reduced tyrosine kinase inhibitor efficacy in non-small cell lung cancer with compound EGFR mutations, highlighting need for personalized targeted therapy.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd78a58e84d0ff5b4641e https://doi.org/10.1186/s12885-026-16912-4

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study uncovers reduced tyrosine kinase inhibitor efficacy in non-small cell lung cancer with compound EGFR mutations, highlighting need for personalized targeted therapy.

Structural classification of EGFR mutations and its association with TKI efficacy against compound and co-mutations in a Chinese NSCLC cohort: a single-center retrospective analysis

Key Points

Discussion

Implication

Cite This Study

Structural classification of EGFR mutations and its association with TKI efficacy against compound and co-mutations in a Chinese NSCLC cohort: a single-center retrospective analysis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider